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Atrial ﬁbrillation (AF) remains the most common and
expensive supraventricular arrhythmia. It is the most
frequently encountered diagnosis among hospitalized pa-
tients and is estimated to cost the U.S. healthcare system
more than $5 billion dollars annually (1). Although catheter
ablation holds the promise of reducing or eliminating AF,
many patients have signiﬁcant comorbidities or have infre-
quent AF episodes and are therefore not ideal candidates
for ablative therapy. In addition, patients with underlying
cardiomyopathy also have a higher AF recurrence rate afterSee page 40catheter ablation (2). Among patients who are at risk of
lethal ventricular arrhythmias and have implantable deﬁ-
brillators, a history of AF is the most important predictor of
inappropriate implantable cardioverter-deﬁbrillator (ICD)
shocks (3). Based on the lack of response to traditional AF
therapies in these patients, alternative therapies are needed
for this patient population.
In the 1990s, signiﬁcant work was performed in animals
(4–8) and then humans (9,10), which led to the develop-
ment of an implanted device that could perform car-
dioversion of AF in ambulatory patients. This eventually
resulted in the development of a company (InControl, Inc.,
Redmond, Washington) and device (Metrix atrioverter)
capable of performing internal atrial deﬁbrillation by using
a shock vector between leads placed in the right atrium
and coronary sinus. The Model 3000 deﬁbrillator could
deliver a maximal shock of 3 J with a biphasic waveform of
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disclose.shock energy of 6 J with a biphasic waveform of 6 ms/6 ms.
Although early pre-clinical and clinical data were promising,
there were several limitations that eventually led to aban-
donment of the device (InControl was bought by Guidant
Corporation [now Boston Scientiﬁc] in 1998, and opera-
tions were closed shortly thereafter).
First and foremost of the device’s limitations was the
recognition that even low-energy shocks are painful to
patients. Although atrial deﬁbrillation required signiﬁ-
cantly less energy than ventricular deﬁbrillation, effective
deﬁbrillation, even with biphasic-tuned waveforms, could
never be achieved below the human pain threshold, re-
ported to range from <1 to 2 J (11–14). Although patients
are willing to tolerate an occasional shock for a life-
threatening ventricular arrhythmia, receiving a painful
shock for AF is unacceptable. Studies were performed to try
to lower the atrial deﬁbrillation thresholds. These attempts
included different types of shock waveforms (15,16), add-
ing an additional electrode (17), and timing shocks to
higher levels of AF organization (18,19). However, these
efforts could not bring the deﬁbrillation threshold below
the pain threshold, increased the risk of complications, or
were too computationally intensive (at the time) to incor-
porate into an implantable device. Some envisioned an
algorithm whereby a patient could electively “trigger” the
shock from an implanted device. In this scenario, patients
could realize they were in AF, take an oral sedative or
narcotic, and then trigger the device to deliver a shock with
a magnet application, thus avoiding an emergency depart-
ment visit and hospital admission. One of the major
concerns about ambulatory atrial deﬁbrillation was the
possible consequence of ventricular proarrhythmia (i.e., an
atrial shock triggering ventricular ﬁbrillation and sudden
death). However, several large studies demonstrated that
this outcome could be completely avoided by only deliv-
ering shocks after long-preceding RR-coupling intervals.
The major unexpected event was the high incidence of early
recurrence of atrial ﬁbrillation (ERAF) after internal deﬁ-
brillation. Although this outcome is occasionally observed
with external deﬁbrillation, ERAF requiring repeat car-
dioversion occurred in up to 25% of atrial shocks. The need
for repeat painful shocks was unacceptable to most patients,
leading to explantation or abandonment of the device in
a signiﬁcant number of patients.
Some standard ICDs include the option of AF recogni-
tion and deﬁbrillation using the standard right ventricular
lead and deﬁbrillation vector; however, this feature is mainly
used for recognition and not therapy, given the aversion to
painful ICD shocks. Other algorithms for AF termination,
such as 50-Hz high-frequency pacing, have been incorpo-
rated into some implantable deﬁbrillators used for ventric-
ular deﬁbrillation, but they are not effective for termination
of AF.
In this issue of the Journal, Janardhan et al. (20) revisit
the concept of internal atrial deﬁbrillation in a canine
model of AF. They use an algorithm they describe as
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50“multistage electrotherapy” (MSE), which consists of
3 stages of treatment in rapid succession. First is a series of
2 low-energy biphasic shocks; second is a series of 6 low-
energy biphasic shocks; and third is a pacing train at 88%
of the AF cycle length. Compared with a single biphasic
shock, the MSE algorithm was able to terminate AF in
this animal model with signiﬁcantly lower energy than
biphasic shocks (0.16  0.16 J vs. 1.48  0.91 J; p < 0.001).
The authors also performed in vitro optical mapping
to analyze the mechanism of AF termination during the
MSE algorithm. They found that the 3 stages were able to
successively eliminate the foci and restore sinus rhythm.
Optical mapping showed the importance of the ﬁrst 2 stages
in establishing a homogeneous phase throughout the tissue
so that the Stage 3 pacing could re-establish sinus rhythm.
The MSE algorithm is interesting, and the 0.16-J mean
deﬁbrillation energy (20) does seem to be conceivably
below the pain threshold in humans. However, the major
limitation, as with all pre-clinical studies, is that pacing-
induced AF in a dog may be very different from persis-
tent AF in humans and AF in other canine models. It has
been shown that atrial deﬁbrillation thresholds can vary
between different canine models of AF (21). In the model
of rapid atrial pacing by Janardhan et al. (20), optical
mapping revealed that the resulting AF was maintained by
“localized foci originating from the pulmonary vein–left
atrium interfaces;” however, the mechanism may be very
different from human AF. With other mechanisms, would
the Stage 1 shocks be able to begin to homogenize the
tissue at lower energy levels? If the AF mechanism was
multiple wavelets, would an increase in energy be needed?
These questions are not meant to short-change the
authors’ contributions; all new concepts must start with
pre-clinical work. However, there are several aspects of
human AF that suggest caution. The ERAF that occurred
during the previous atrial deﬁbrillator trials has not been
replicated in animal models. Although the Stage 3
entrainment pacing train may help reduce this, we have no
idea if this method will be efﬁcacious in humans. The
MSE algorithm is complex, and we have little background
to understand how the authors developed this sequence.
Did they ﬁrst try Stages 1 and 2 alone? Are 6 shocksdand
not 5dalways required in Stage 2? Is Stage 3 pacing
always required? Without this background information, it
makes it difﬁcult to completely understand the efﬁcacy of
the algorithm. It also limits the potential application to
human AF, in which the mechanism of AF maintenance
may be different.
Overall, the authors (20) have provided a novel algorithm
that may “resurrect” the concept of internal atrial deﬁbril-
lation. Such an algorithm would be of tremendous impor-
tance if it could be incorporated into current deﬁbrillators
by using an additional coronary sinus lead. However, the
extension from the canine model to humans is far from
assured. The next steps should involve testing the algorithm
in patients undergoing AF ablation by using temporaryintracardiac catheters in which atrial deﬁbrillation is already
performed. The ﬁnal step in determining the pain threshold
for the MSE algorithm will require thoughtful evaluation
in a dedicated group of patients. We are indebted to the
authors for bringing back the concept of internal atrial
deﬁbrillation with a new twist. Hopefully, there will be more
to follow.Reprint requests and correspondence: Dr. Edward P. Ger-
stenfeld, Section of Cardiac Electrophysiology, University of
California, San Francisco; MU-East 4th Floor, 500 Parnassus
Avenue, San Francisco, California 94143. E-mail: egerstenfeld@
medicine.ucsf.edu.REFERENCES
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